NCT01808482: A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) |
|
|
| Terminated | 1 | 16 | Europe | Part A: 100 mg/mL GSK2618960, Part A: matching placebo, Part B: Dose of GSK2618960 decided from Part A, Part B: matching placebo, Part C: Dose of GSK2618960 decided from Part A and B | GlaxoSmithKline | Multiple Sclerosis, Relapsing-Remitting | 08/13 | 08/13 | | |
